Literature DB >> 18419456

Vaccination in patients with chronic rheumatic or autoimmune diseases.

T Glück1, U Müller-Ladner.   

Abstract

Patients who have chronic rheumatic or autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, or vasculitides, show a risk of infection that is at least 2-fold greater than that for healthy individuals. This increased risk is not only a result of the aberrant immunologic reaction itself but also can be attributed to the immunosuppressive therapy required to control the activity of the underlying disease and the associated organ complications. Vaccination is an option for a substantial number of these infections. In this context, pneumococcal and influenza vaccines are the best evaluated and are recommended by standard vaccination guidelines. Some studies have found mildly impaired immune responses to vaccines among patients receiving long-term immunosuppressive therapy, but postvaccination antibody titers are usually sufficient to provide protection for the majority of immunized individuals. The accumulated data on the safety and effectiveness of vaccines warrant immunization with the majority of vaccines for patients with chronic autoimmune or rheumatic diseases, especially vaccination against influenza and pneumococci. Vaccination protocols for this population should be better implemented in daily clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419456     DOI: 10.1086/587063

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality.

Authors:  Sonali P Desai; Alexander Turchin; Lara E Szent-Gyorgyi; Michael Weinblatt; Jonathan Coblyn; Daniel H Solomon; Allen Kachalia
Journal:  Rheumatology (Oxford)       Date:  2010-10-24       Impact factor: 7.580

Review 3.  [Vaccination and multiple sclerosis].

Authors:  M Löbermann; A Winkelmann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

Review 4.  Vaccines and autoimmunity.

Authors:  Nancy Agmon-Levin; Ziv Paz; Eitan Israeli; Yehuda Shoenfeld
Journal:  Nat Rev Rheumatol       Date:  2009-11       Impact factor: 20.543

Review 5.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

6.  Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis.

Authors:  Toshiaki Kogure; Naoyuki Harada; Takeshi Tatsumi; Hiroshi Fujinaga
Journal:  Clin Rheumatol       Date:  2014-01-21       Impact factor: 2.980

7.  Vaccination in adults with autoimmune rheumatic diseases.

Authors:  Timothy S H Kwok; Michael Libman; Shirley L Lake
Journal:  CMAJ       Date:  2019-09-09       Impact factor: 8.262

8.  Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.

Authors:  A Chioato; E Noseda; S D Felix; M Stevens; G Del Giudice; S Fitoussi; A Kleinschmidt
Journal:  Clin Vaccine Immunol       Date:  2010-10-20

Review 9.  Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases.

Authors:  Despoina Papadopoulou; Nikolaos V Sipsas
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

10.  The effect of infliximab on antiviral antibody profiles in patients with rheumatoid arthritis.

Authors:  Ilana Kaufman; Yolanda Braun Moscovici; Yair Abudi; Denit Sofer; Ella Mendelson; Alexandra Balbir-Gurman; Dan Caspi; Ori Elkayam
Journal:  Rheumatol Int       Date:  2009-05-20       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.